Curcumin Conjugates for Treating and Preventing Cancers
    32.
    发明申请
    Curcumin Conjugates for Treating and Preventing Cancers 有权
    用于治疗和预防癌症的姜黄素偶联物

    公开(公告)号:US20110263500A1

    公开(公告)日:2011-10-27

    申请号:US13119549

    申请日:2009-09-16

    摘要: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.

    摘要翻译: 将LHRH与姜黄素(LHRH-姜黄素)结合显着提高姜黄素的生物利用度,将其靶向表达LHRH受体的细胞,促进静脉内施用,并增加姜黄素的抗癌功效。 该缀合物可用于表达LHRH受体的癌细胞:胰腺,前列腺,乳腺,睾丸,子宫,卵巢,黑素瘤。 LH-姜黄素结合物可用于表达LH受体的癌细胞:前列腺,乳腺,卵巢,睾丸,子宫,胰腺和黑素瘤。

    Anti-fibril peptides
    33.
    发明授权
    Anti-fibril peptides 有权
    抗原纤维肽

    公开(公告)号:US07345022B2

    公开(公告)日:2008-03-18

    申请号:US10666095

    申请日:2003-09-18

    摘要: Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's disease, Parkinson's Disease, Creutzfeldt-Jakob Disease, Huntington's Disease, and Type II Diabetes. These new β-strand mimics (β-sheet “blockers”), containing Cα,α-disubstituted amino acids, specifically interact with and block the development of the β-sheet structure of the developing fibrils of amyloid diseases, such as Alzheimer's disease amyloid β-peptide (Aβ). We have discovered that oligomerization of β-sheet structures, including those implicated in amyloid-associated diseases, may be inhibited or even reversed by the presence of extended peptide structures that have only one edge available for hydrogen bonding. Without a second edge that is also available for hydrogen bonding, the extension of a developing β-sheet is blocked by binding to the novel peptides.

    摘要翻译: 公开了可用作淀粉样蛋白发生抑制剂的新型肽,作为淀粉样蛋白毒性的抑制剂,以及作为淀粉样蛋白相关疾病如阿尔茨海默氏病,帕金森氏病,克雅氏病,亨廷顿氏病和II型糖尿病的治疗剂。 这些新的β链模拟物(β-片段“阻断剂”),含有Cα,α - 二取代的氨基酸,特异性地相互作用并阻断了发展中的原纤维的β-折叠结构 淀粉样蛋白疾病,如阿尔茨海默病淀粉样蛋白β-肽(Abeta)。 我们已经发现,β-片结构的低聚,包括涉及淀粉样蛋白相关疾病的那些,可能被抑制或甚至被仅具有一个可用于氢键的边缘的延伸肽结构的存在所逆转。 没有可用于氢键的第二边缘,通过与新肽的结合阻断了显影的β-折叠片的延伸。

    Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process
    34.
    发明授权
    Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process 有权
    耦合聚合酶链反应 - 限制性内切酶消化 - 连接酶检测反应过程

    公开(公告)号:US07014994B1

    公开(公告)日:2006-03-21

    申请号:US09528014

    申请日:2000-03-17

    IPC分类号: C12Q1/68 C12P19/34 C07H21/04

    摘要: The present invention provides a method for identifying one or more low abundance sequences differing by one or more single-base changes, insertions, or deletions, from a high abundance sequence in a plurality of target nucleotide sequences. The high abundance wild-type sequence is selectively removed using high fidelity polymerase chain reaction analog conversion, facilitated by optimal buffer conditions, to create a restriction endonuclease site in the high abundance wild-type gene, but not in the low abundance mutant gene. This allows for digestion of the high abundance DNA. Subsequently the low abundant mutant DNA is amplified and detected by the ligase detection reaction assay. The present invention also relates to a kit for carrying out this procedure.

    摘要翻译: 本发明提供了一种用于从多个靶核苷酸序列中的高丰度序列鉴定一个或多个不同于一个或多个单碱基变化,插入或缺失的低丰度序列的方法。 使用高保真聚合酶链反应模拟转化,通过最佳缓冲条件促进高丰度野生型序列,在高丰度野生型基因中产生限制性内切核酸酶位点而不是在低丰度突变基因中产生限制性内切核酸酶位点。 这样可以消化高丰度DNA。 随后,通过连接酶检测反应测定扩增和检测低丰度突变体DNA。 本发明还涉及用于实施该方法的试剂盒。